Purdue Pharma LP hit Teva Pharmaceuticals USA Inc. with a suit in federal court in New York accusing Teva of patent infringement for seeking approval for a generic "abuse-proof" version of the painkiller OxyContin.
Upon information belief, Teva submitted ANDA No. 202455 to the FDA under 505(j) of Federal Food, Drug and Cosmetic act (21 USC 355(j)), seeking approval to engage in the commercial manufacture, use, sale, offer or importation of generic Oxycodone hydrochloride extended release tablets 10mg, 15mg, 20mg, 30mg, 40mg, 60m, 80 mg, based on the Reference Listed Drug (RLD) Oxycodone ®, which is the subject of the approved NDA No. 022272, before the expiration of US 8,337,888 and US 8,309,060.
Complaint for Patent Infringement
Civil Action No. 1:13-cv-04606-UA; no judge yet assigned.
Filed on July 2, 2013 in the U.S. District Court for the Southern District of New York;
Patents in suit: US 8,337,888 and US 8,309,060.
Upon information belief, Teva submitted ANDA No. 202455 to the FDA under 505(j) of Federal Food, Drug and Cosmetic act (21 USC 355(j)), seeking approval to engage in the commercial manufacture, use, sale, offer or importation of generic Oxycodone hydrochloride extended release tablets 10mg, 15mg, 20mg, 30mg, 40mg, 60m, 80 mg, based on the Reference Listed Drug (RLD) Oxycodone ®, which is the subject of the approved NDA No. 022272, before the expiration of US 8,337,888 and US 8,309,060.
Complaint for Patent Infringement
Civil Action No. 1:13-cv-04606-UA; no judge yet assigned.
Filed on July 2, 2013 in the U.S. District Court for the Southern District of New York;
Patents in suit: US 8,337,888 and US 8,309,060.